ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Rheumatology · Arthritis Rheumatol · 2026-04-17

Exploratory post hoc analysis of a phase 3 trial in 746 DMARD-naive, ACPA-positive patients with early RA: high baseline IL-10 predicted better week-52 response to abatacept plus MTX vs placebo plus MTX, and 47 of 103 biomarkers fell more with abatacept.

Secondary analysisn = 746
Liu et al. Baseline Interleukin-10 Levels as a Predictive Biomarker for Achieving Clinical Response With Abatacept in Patients Who Were Disease-Modifying Antirheumatic Drug Naive and Anti-Citrullinated Protein Antibody Positive With Early Rheumatoid Arthritis
Rheumatology · Lancet Rheumatol · 2026-04-01

Secondary analysis of NORD-STAR (795 patients, early rheumatoid arthritis): all arms improved patient-reported outcomes at 48 weeks; certolizumab pegol, abatacept or tocilizumab vs active conventional therapy gave somewhat larger pain and fatigue gains; differences were small.

Secondary analysisn = 812
Lampa et al. Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial
Rheumatology · Semin Arthritis Rheum · 2026-01-12

Post hoc analysis of AVERT and AVERT-2 (ACPA-positive early RA): DAS28-CRP remission at 6/12 months was 27%/39% with methotrexate (n=388) and 43%/53% with abatacept plus methotrexate (n=743); only baseline DAS28 and early response consistently predicted remission.

Secondary analysis
Bergstra et al. Predictors of achieving clinical remission in ACPA-positive RA-patients treated with abatacept and methotrexate and methotrexate monotherapy: a post-hoc analysis of the AVERT and AVERT-II trials

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.